Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 2Substance-Related Disorders 1Smoking Cessation 1Head and Neck Neoplasms 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Acceptance and Commitment Therapy × 30 days × Clear all
NCT01098955 2026-05-22

Smoking Cessation Treatment for Head & Neck Cancer Patients

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
51 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasms, Smoking Cessation

NCT05643027 2026-05-14

ACTION

Dana-Farber Cancer Institute

Phase NA Completed
40 enrolled

Neoplasms, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡